Oryzon Reveals Exciting Results from PORTICO Trial
Oryzon Genomics, known for its innovative work in epigenetics, has recently caught attention by sharing crucial results from their Phase IIb trial of vafidemstat at the European College of Neuropsychopharmacology (ECNP) Congress. This study, called PORTICO, aims to find effective treatments for Borderline Personality Disorder (BPD), a condition that significantly disrupts emotional stability and relationships for those who suffer from it.
Highlighting Key Improvements
The final results from the PORTICO trial show impressive progress in treating BPD. A key finding was a notable decrease in Trait Anger, as assessed by the State-Trait Anger Expression Inventory 2 (STAXI-2). This reduction in agitation and aggression was so substantial that it achieved a nominal statistical significance with a p-value of 0.0071 over Weeks 8 to 12, improving upon earlier top-line data.
Assessing Overall Disease Severity
Moreover, the Borderline Evaluation of Severity (BEST), which measures the overarching severity of BPD, demonstrated significant improvement at Weeks 8 to 12 with a p-value of 0.0260. This indicates real progress compared to past results. The range of efficacy endpoints showcased by the T-Forest plot analysis confirmed vafidemstat's superior performance relative to placebo.
Clinical Impact of PORTICO
This trial encompassed 211 participants from around the globe, who were randomly assigned to receive either vafidemstat or a placebo. The robust design of this study, alongside the inclusion of diverse clinical sites, generated compelling evidence that vafidemstat has the potential to revolutionize treatment for BPD. Statistical significance was achieved across various endpoints, pointing to vafidemstat as a novel treatment option without the adverse side effects often seen with current off-label therapies.
Future Strategies for the Company
Dr. Michael Ropacki, Oryzon's Chief Medical Officer, expressed strong enthusiasm regarding the PORTICO results, highlighting not only the significant clinical advantages of vafidemstat but also its potential as a fresh alternative to current BPD management strategies. This progress positions Oryzon as a leader in addressing the treatment needs of approximately 1.4 million BPD patients who currently depend on off-label prescriptions.
Insights from Regulatory Dialogues
In light of these encouraging findings, Oryzon has actively pursued discussions with the FDA concerning the next phases, including potential registrational Phase III studies for vafidemstat in treating BPD. A positive outcome from the FDA could lead to the launch of the PORTICO-2 Phase III trial, setting Oryzon on track to be the first company to advance a drug into this essential stage of development for BPD.
Safety and Tolerability Observations
Throughout the trial, vafidemstat demonstrated a strong safety profile, with adverse events aligning closely with those seen in earlier studies and no new safety concerns surfacing. Notably, patients receiving vafidemstat showed a reduced tendency for self-harm, which is a promising finding for addressing the complex emotional challenges faced by individuals with BPD.
About Oryzon Genomics
Since its founding in 2000, Oryzon has become a leader in utilizing epigenetics to develop personalized medicine approaches for CNS disorders and oncology. The company’s innovative pipeline, featuring two promising LSD1 inhibitors—vafidemstat and iadademstat—demonstrates their commitment to improving therapeutic options for patients with significant unmet medical needs. Their research focus aims to tackle the symptoms of complex conditions while also enhancing the overall quality of life for those affected.
Frequently Asked Questions
What is the PORTICO trial about?
The PORTICO trial is a Phase IIb study examining the efficacy and safety of vafidemstat for patients with Borderline Personality Disorder, producing promising findings.
What are the key findings from the PORTICO trial?
The trial showed significant reductions in agitation and overall disease severity, indicating vafidemstat's effectiveness compared to placebo.
How many participants were involved in the study?
The trial included 211 patients, who were randomly assigned to receive either vafidemstat or a placebo for comparative evaluation.
What discussions has Oryzon had with the FDA?
Oryzon has been in discussions with the FDA about launching a registrational Phase III trial for vafidemstat, based on the promising results from the PORTICO study.
What is vafidemstat?
Vafidemstat (ORY-2001) is an oral LSD1 inhibitor aimed at addressing cognitive impairment and emotional instability often found in psychiatric disorders.
